Kidney Cancer Drugs Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020
Kidneys are among the most crucial organs of the human body. Their role in regulating blood pressure and serving homeostatic functions is critical in maintaining the balance of nutrients and toxins in the body. Kidneys serve as natural blood filters, removing the water-soluble wastes and reabsorbing the essential elements from the blood. Since they play such a crucial role, kidneys require constant regeneration of dead nephrons and proper blood circulation to maintain healthy cell growth, due to which, they are susceptible to metastasis and cancerous tumors. Renal cell carcinoma, the most common type of kidney cancer, is among the toughest cancers to treat, especially in the advanced stages. Until 1980’s, the treatment of kidney cancer included surgical removal of the kidneys. The treatment later progressed to laparoscopic removal of the tumor-affected part of the kidneys, significantly increasing the survival rate and patient comfort. Drugs are usually given to stage four advanced renal cell carcinoma patients with disease progression. Various forms of cancer treatment mechanism have been implemented among the presently approved drugs for kidney cancer; these include, VEGF (Vascular Endothelial Growth Factor) inhibitor, angiogenesis inhibitor, cytokine therapy, and immune modulation therapy to name a few.
Kidneys are among the most crucial organs of the human body. Their role in regulating blood pressure and serving homeostatic functions is critical in maintaining the balance of nutrients and toxins in the body. Kidneys serve as natural blood filters, removing the water-soluble wastes and reabsorbing the essential elements from the blood. Since they play such a crucial role, kidneys require constant regeneration of dead nephrons and proper blood circulation to maintain healthy cell growth, due to which, they are susceptible to metastasis and cancerous tumors. Renal cell carcinoma, the most common type of kidney cancer, is among the toughest cancers to treat, especially in the advanced stages. Until 1980’s, the treatment of kidney cancer included surgical removal of the kidneys. The treatment later progressed to laparoscopic removal of the tumor-affected part of the kidneys, significantly increasing the survival rate and patient comfort. Drugs are usually given to stage four advanced renal cell carcinoma patients with disease progression. Various forms of cancer treatment mechanism have been implemented among the presently approved drugs for kidney cancer; these include, VEGF (Vascular Endothelial Growth Factor) inhibitor, angiogenesis inhibitor, cytokine therapy, and immune modulation therapy to name a few.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Transparency <strong>Market</strong><br />
Research<br />
<strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong> - <strong>Global</strong> <strong>Industry</strong> <strong>Analysis</strong>,<br />
<strong>Pipeline</strong> <strong>Analysis</strong>, <strong>Size</strong>, <strong>Share</strong>, <strong>Growth</strong>, <strong>Trends</strong> <strong>and</strong><br />
<strong>Forecast</strong> <strong>2014</strong> - <strong>2020</strong><br />
Published Date<br />
2015-01-23<br />
82 Page Report<br />
Buy Now<br />
Request Sample<br />
Press Release<br />
<strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong> Expected to Reach USD 4.5 Billion<br />
<strong>Global</strong>ly in <strong>2020</strong><br />
Transparency <strong>Market</strong> Research<br />
State Tower,<br />
90, State Street, Suite 700.<br />
Albany, NY 12207<br />
United States<br />
www.transparencymarketresearch.com<br />
sales@transparencymarketresearch.com
<strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong><br />
REPORT DESCRIPTION<br />
<strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong><br />
<strong>Size</strong>, <strong>Share</strong>, <strong>Growth</strong>, <strong>Trends</strong> <strong>and</strong> <strong>Forecast</strong> <strong>2014</strong> <strong>–</strong> <strong>2020</strong><br />
- <strong>Global</strong> <strong>Industry</strong> <strong>Analysis</strong>, <strong>Pipeline</strong> <strong>Analysis</strong>,<br />
<strong>Kidney</strong>s are among the most crucial organs of the human body. Their role in<br />
regulating blood pressure <strong>and</strong> serving homeostatic functions is critical in<br />
maintaining the balance of nutrients <strong>and</strong> toxins in the body. <strong>Kidney</strong>s serve as<br />
natural blood filters, removing the water-soluble wastes <strong>and</strong> reabsorbing the<br />
essential elements from the blood. Since they play such a crucial role, kidneys<br />
require constant regeneration of dead nephrons <strong>and</strong> proper blood circulation to<br />
maintain healthy cell growth, due to which, they are susceptible to metastasis <strong>and</strong><br />
cancerous tumors. Renal cell carcinoma, the most common type of kidney cancer,<br />
is among the toughest cancers to treat, especially in the advanced stages. Until<br />
1980’s, the treatment of kidney cancer included surgical removal of the kidneys.<br />
The treatment later progressed to laparoscopic removal of the tumor-affected part<br />
of the kidneys, significantly increasing the survival rate <strong>and</strong> patient comfort.<br />
<strong>Drugs</strong> are usually given to stage four advanced renal cell carcinoma patients with<br />
disease progression. Various forms of cancer treatment mechanism have been<br />
implemented among the presently approved drugs for kidney cancer; these<br />
include, VEGF (Vascular Endothelial <strong>Growth</strong> Factor) inhibitor, angiogenesis<br />
inhibitor, cytokine therapy, <strong>and</strong> immune modulation therapy to name a few.<br />
Browse the full <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong> Report at :<br />
http://www.transparencymarketresearch.com/kidney-cancer-drugsmarket.html<br />
Transparency <strong>Market</strong> Research<br />
2
<strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong><br />
This research report provides a detailed analysis of the global kidney cancer drugs<br />
market <strong>and</strong> helps in underst<strong>and</strong>ing the various driving factors of this market. The<br />
market overview section provides analysis of the market dynamics <strong>and</strong> trends<br />
such as drivers, restraints, <strong>and</strong> opportunities that influence the current nature of<br />
the market. The section also forecasts the future scenario of the market. The<br />
executive summary gives detailed insights about the report <strong>and</strong> the market in<br />
general. It also contains a market snapshot, which provides a glimpse into the<br />
current scenario of the global kidney cancer drugs market. Event impact analysis<br />
<strong>and</strong> other market dynamics tools such as market attractiveness analysis,<br />
regulatory framework analysis, <strong>and</strong> market share analysis have also been<br />
explained in the market overview section of the report, in order to deliver a<br />
thorough analysis of the overall competitive scenario in the global kidney cancer<br />
drugs market.<br />
Get Free Sample Report <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong> :<br />
http://www.transparencymarketresearch.com/sample/sample.php?<br />
flag=S&rep_id=537<br />
The global kidney cancer drugs market is segmented on the basis of major<br />
br<strong>and</strong>ed drugs produced <strong>and</strong> geography. By major br<strong>and</strong>ed drugs, the market is<br />
further segmented into the major br<strong>and</strong>s approved for the indication of renal cell<br />
carcinoma such as Afinitor (Everolimus), Avastin (Bevacizumab), Inlyta (Axitinib),<br />
Nexavar (Sorafenib), Proleukin (Aldesleukin/Interleukin-2), Sutent (Sunitinib),<br />
Torisel (Temsirolimus), <strong>and</strong> Votrient (Pazopanib). The report also includes pipeline<br />
analysis of the most potential drugs, which are currently in phase 2 <strong>and</strong> phase 3<br />
trials for renal cell carcinoma indication. Considering 2013 as the base year for<br />
estimating the market size <strong>and</strong> 2012 as the historical year, the market size<br />
estimations for the period from 2012 to <strong>2020</strong> have been provided for each of the<br />
major br<strong>and</strong>ed drugs mentioned above in terms of USD million. The CAGR (%) of<br />
Transparency <strong>Market</strong> Research<br />
3
<strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong><br />
each market segment for the forecast period between 2012 to 2016 <strong>and</strong> 2016 to<br />
<strong>2020</strong> has also been provided along with market size estimations.<br />
Browse the full <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong> press release at :<br />
http://www.transparencymarketresearch.com/pressrelease/kidneycancer-drugs-market.htm<br />
Geographically, the global kidney cancer drugs market has been segmented into<br />
four major regions: North America, Europe, Asia Pacific, <strong>and</strong> Rest of World (RoW),<br />
Russia being included in the RoW region. The market size estimations for the<br />
period between 2012 <strong>and</strong> <strong>2020</strong> <strong>and</strong> market forecast for the period <strong>2014</strong> - <strong>2020</strong><br />
have been provided for each of these regions by revenue in terms of USD million<br />
along with the CAGR for the forecast period <strong>2014</strong> to <strong>2020</strong>. This study further<br />
offers market recommendations for market players of the global kidney cancer<br />
drugs market, which include factors that may play a critical role in enhancing or<br />
boosting the market share of companies in the near future. The report also<br />
advices measures that need to be considered to achieve success for kidney<br />
cancer drug manufacturers <strong>and</strong> marketers globally.<br />
The report concludes with company profiles, which include key information about<br />
the major players actively participating in the kidney cancer drugs market. The<br />
report profiles the market players in terms of company overview, financial<br />
overview, business strategy, recent developments, <strong>and</strong> product portfolio. The<br />
companies featured in this report have exclusive patent rights to the following<br />
major br<strong>and</strong>ed drugs: Novartis AG., F. Hoffman-La Roche., Pfizer, Inc., Bayer<br />
Pharma AG., <strong>and</strong> GlaxoSmithKline, plc.<br />
Transparency <strong>Market</strong> Research<br />
4
<strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong><br />
The global kidney cancer drugs market is segmented as follows:<br />
<strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong>, by Major Br<strong>and</strong>ed <strong>Drugs</strong><br />
Sutent (Sunitinib)<br />
Nexavar (Sorafenib)<br />
Afinitor (Everolimus)<br />
Votrient (Pazopanib)<br />
Inlyta (Axitinib)<br />
Avastin (Bevacizumab)<br />
Torisel (Temsirolimus)<br />
Proleukin (Aldesleukin)<br />
<strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong>, by Geography<br />
Transparency <strong>Market</strong> Research<br />
5
<strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong><br />
North America<br />
Europe<br />
Asia Pacific<br />
Rest of the World (RoW)<br />
TABLE OF CONTENT<br />
Chapter 1 Preface<br />
1.1 Report Description<br />
1.2 <strong>Market</strong> Segmentation<br />
1.3 Research Methodology<br />
1.4 Assumptions<br />
Chapter 2 Executive Summary<br />
2.1 <strong>Market</strong> Snapshot: <strong>Global</strong> <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong><br />
2.2 Comparative <strong>Analysis</strong>: <strong>Global</strong> <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong>, By Geography, 2013 <strong>and</strong> <strong>2020</strong> (Value %)<br />
Transparency <strong>Market</strong> Research<br />
6
<strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong><br />
Chapter 3 <strong>Global</strong> <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong> Overview<br />
3.1 <strong>Market</strong> Dynamics <strong>and</strong> Overview<br />
3.2 <strong>Market</strong> Drivers<br />
3.2.1 Rising Incidence of <strong>Kidney</strong> <strong>Cancer</strong> Expected to Boost <strong>Market</strong> <strong>Growth</strong><br />
3.2.2 Increasing Geriatric Population Likely to Fuel the <strong>Growth</strong> of <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong><br />
3.2.2.1.1 <strong>Global</strong> Percentage Change in the World’s Population by Age: 2010-2050<br />
3.2.3 Approval of Novel Molecules is Expected to Drive <strong>Market</strong> <strong>Growth</strong><br />
3.3 <strong>Market</strong> Restraints<br />
3.3.1 High Prices of Br<strong>and</strong>ed <strong>Cancer</strong> <strong>Drugs</strong> might Impede the <strong>Growth</strong> of the <strong>Market</strong><br />
3.3.2 Increasing Preference for Generic Drug Variants might Negatively Influence the <strong>Market</strong> <strong>Growth</strong><br />
3.4 <strong>Market</strong> Opportunities<br />
3.4.1 Focusing on Emerging <strong>Market</strong>s<br />
3.5 Event Impact <strong>Analysis</strong><br />
3.6 Regulatory Framework<br />
3.7 <strong>Market</strong> Attractiveness <strong>Analysis</strong>: <strong>Global</strong> <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong>, by Geography<br />
3.8 <strong>Market</strong> <strong>Share</strong> <strong>Analysis</strong>: <strong>Global</strong> <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong>, by Key Players, 2013 (Value %)<br />
Chapter 4 <strong>Global</strong> <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong>, by Major Br<strong>and</strong>ed <strong>Drugs</strong><br />
4.1 Overview<br />
4.1.1 <strong>Global</strong> <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong> Revenue, by Major Br<strong>and</strong>ed <strong>Drugs</strong>, 2012 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
4.2 Sutent (Sunitinib)<br />
Transparency <strong>Market</strong> Research<br />
7
<strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong><br />
4.2.1 <strong>Global</strong> Sutent (Sunitinib) <strong>Market</strong> Revenue, 2012 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
4.3 Nexavar (Sorafenib)<br />
4.3.1 <strong>Global</strong> Nexavar (Sorafenib) <strong>Market</strong> Revenue, 2012 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
4.4 Afinitor (Everolimus)<br />
4.4.1 <strong>Global</strong> Afinitor (Everolimus) <strong>Market</strong> Revenue, 2012 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
4.5 Votrient (Pazopanib)<br />
4.5.1 <strong>Global</strong> Votrient (Pazopanib) <strong>Market</strong> Revenue, 2012 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
4.6 Inlyta (Axitinib)<br />
4.6.1 <strong>Global</strong> Inlyta (Axitinib) <strong>Market</strong> Revenue, 2012 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
4.7 Avastin (Bevacizumab)<br />
4.7.1 <strong>Global</strong> Avastin (Bevacizumab) <strong>Market</strong> Revenue, 2012 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
4.8 Torisel (Temsirolimus)<br />
4.8.1 <strong>Global</strong> Torisel (Temsirolimus) <strong>Market</strong> Revenue, 2012 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
4.9 Proleukin (Aldesleukin)<br />
4.9.1 <strong>Global</strong> Proleukin (Aldesleukin) <strong>Market</strong> Revenue, 2012 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
Chapter 5 <strong>Global</strong> <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong>, <strong>Pipeline</strong> <strong>Analysis</strong><br />
5.1 Overview<br />
5.1.1 <strong>Global</strong> <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong> Revenue, by <strong>Pipeline</strong> <strong>Drugs</strong>, 2015 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
5.2 Opdivo (Nivolumab) (Bristol-Myers Squibb)<br />
5.2.1 <strong>Global</strong> Opdivo <strong>Market</strong> Revenue, 2015 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
Transparency <strong>Market</strong> Research<br />
8
<strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong><br />
5.3 Keytruda (Anti PD 1) (Pembrolizumab) (Merck & Co., Inc.)<br />
5.3.1 <strong>Global</strong> Keytruda <strong>Market</strong> Revenue, 2015 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
5.4 Cabozantinib (XL184) (Exelixis, Inc.)<br />
5.4.1 <strong>Global</strong> Cabozantinib <strong>Market</strong> Revenue, 2017 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
5.5 AGS-003 (Argus Therapeutics, Inc.)<br />
5.5.1 <strong>Global</strong> AGS-003 <strong>Market</strong> Revenue, 2017 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
5.6 Dovitinib (TK1258) [Novartis AG]<br />
5.6.1 <strong>Global</strong> Dovitinib <strong>Market</strong> Revenue, 2018 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
Chapter 6 <strong>Global</strong> <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong>, by Geography<br />
6.1 Overview<br />
6.1.1 <strong>Global</strong> <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong> Revenue, by Geography, 2012 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
6.2 North America<br />
6.2.1 North America <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong> Revenue, 2012<strong>–</strong><strong>2020</strong> (USD Million)<br />
6.3 Europe<br />
6.3.1 Europe <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong> Revenue, 2012 - <strong>2020</strong> (USD Million)<br />
6.4 Asia Pacific<br />
6.4.1 Asia Pacific <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong> Revenue, 2012 - <strong>2020</strong> (USD Million)<br />
6.5 Rest of the World (RoW)<br />
6.5.1 Rest of the World <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong> Revenue, 2012 - <strong>2020</strong> (USD Million)<br />
Transparency <strong>Market</strong> Research<br />
9
<strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong><br />
Chapter 7 Recommendations<br />
Chapter 8 Company Profiles<br />
8.1 Bayer AG<br />
8.1.1 Company Overview<br />
8.1.2 Financial Overview<br />
8.1.3 Product Portfolio<br />
8.1.4 Business Strategy<br />
8.1.5 Recent Developments<br />
8.2 F. Hoffmann-La Roche, Ltd.<br />
8.2.1 Company Overview<br />
8.2.2 Financial Overview<br />
8.2.3 Product Portfolio<br />
8.2.4 Business Strategy<br />
8.2.5 Recent Developments<br />
8.3 GlaxoSmithKline, plc<br />
8.3.1 Company Overview<br />
8.3.2 Financial Overview<br />
8.3.3 Product Portfolio<br />
8.3.4 Business Strategy<br />
8.3.5 Recent Developments<br />
Transparency <strong>Market</strong> Research<br />
10
<strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong><br />
8.4 Novartis AG<br />
8.4.1 Company Overview<br />
8.4.2 Financial Overview<br />
8.4.3 Product Portfolio<br />
8.4.4 Business Strategy<br />
8.4.5 Recent Developments<br />
8.5 Pfizer, Inc.<br />
8.5.1 Company Overview<br />
8.5.2 Financial Overview<br />
8.5.3 Product Portfolio<br />
8.5.4 Business Strategy<br />
8.5.5 Recent Developments<br />
List of Figures<br />
FIG. 1 <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong>: <strong>Market</strong> Segmentation<br />
FIG. 2 <strong>Global</strong> <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong>, by Major Br<strong>and</strong>ed <strong>Drugs</strong>, 2013 (USD Million)<br />
FIG. 3 <strong>Global</strong> <strong>Kidney</strong> <strong>Cancer</strong> <strong>Pipeline</strong> <strong>Drugs</strong> <strong>Market</strong> (USD Million)<br />
FIG. 4 Comparative <strong>Analysis</strong>: <strong>Global</strong> <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong>, by Geography, 2013 <strong>and</strong> <strong>2020</strong> (Value %)<br />
FIG. 5 <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong>, Drivers <strong>and</strong> Restraints<br />
FIG. 6 <strong>Global</strong> Percentage Change in the World’s Population by Age: 2010 - 2050<br />
FIG. 7 Major Developments in <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong><br />
Transparency <strong>Market</strong> Research<br />
11
<strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong><br />
FIG. 8 <strong>Market</strong> Attractiveness <strong>Analysis</strong>: <strong>Global</strong> <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong>, by Geography<br />
FIG. 9 <strong>Market</strong> <strong>Share</strong> <strong>Analysis</strong>: <strong>Global</strong> <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong>, by Key Players, 2013 (Value %)<br />
FIG. 10 <strong>Global</strong> Sutent (Sunitinib) <strong>Market</strong> Revenue, 2012 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
FIG. 11 <strong>Global</strong> Nexavar (Sorafenib) <strong>Market</strong> Revenue, 2012 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
FIG. 12 <strong>Global</strong> Afinitor (Everolimus) <strong>Market</strong> Revenue, 2012 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
FIG. 13 <strong>Global</strong> Votrient (Pazopanib) <strong>Market</strong> Revenue, 2012 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
FIG. 14 <strong>Global</strong> Inlyta (Axitinib) <strong>Market</strong> Revenue, 2012 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
FIG. 15 <strong>Global</strong> Avastin (Bevacizumab) <strong>Market</strong> Revenue, 2012 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
FIG. 16 <strong>Global</strong> Torisel (Temsirolimus) <strong>Market</strong> Revenue, 2012 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
FIG. 17 <strong>Global</strong> Proleukin (Aldesleukin) <strong>Market</strong> Revenue, 2012 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
FIG. 18 <strong>Global</strong> Opdivo <strong>Market</strong> Revenue, 2015 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
FIG. 19 <strong>Global</strong> Keytruda <strong>Market</strong> Revenue, 2015 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
FIG. 20 <strong>Global</strong> Cabozantinib <strong>Market</strong> Revenue, 2017 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
FIG. 21 <strong>Global</strong> AGS-003 <strong>Market</strong> Revenue, 2017 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
FIG. 22 <strong>Global</strong> Dovitinib <strong>Market</strong> Revenue, 2018 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
FIG. 23 North America <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong> Revenue, 2012 - <strong>2020</strong> (USD Million)<br />
FIG. 24 Europe <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong> Revenue, 2012 - <strong>2020</strong> (USD Million)<br />
FIG. 25 Asia Pacific <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong> Revenue, 2012 - <strong>2020</strong> (USD Million)<br />
FIG. 26 Rest of the World <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong> Revenue, 2012 - <strong>2020</strong> (USD Million)<br />
FIG. 27 Bayer AG: Annual Revenue, 2011 <strong>–</strong> 2013 (USD Million)<br />
FIG. 28 F. Hoffmann-La Roche, Ltd.: Annual Revenue, 2011 <strong>–</strong> 2013 (USD Million)<br />
Transparency <strong>Market</strong> Research<br />
12
<strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong><br />
FIG. 29 GlaxoSmithKline, plc.: Annual Revenue, 2011 <strong>–</strong> 2013 (USD Million)<br />
FIG. 30 Annual Revenue: Novartis AG 2011 <strong>–</strong> 2013 (USD Million)<br />
FIG. 31 Pfizer, Inc.: Annual Revenue, 2011 <strong>–</strong> 2013 (USD Million)<br />
List of Tables<br />
TABLE 1 <strong>Market</strong> Snapshot: <strong>Global</strong> <strong>Kidney</strong> <strong>Cancer</strong> <strong>Market</strong><br />
TABLE 2 Stages of RCC, According to the U.S. TNM Classification<br />
TABLE 3 <strong>Global</strong> <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong> Revenue, by Major Br<strong>and</strong>ed <strong>Drugs</strong>, 2012 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
TABLE 4 <strong>Global</strong> <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong> Revenue, by <strong>Pipeline</strong> <strong>Drugs</strong>, 2015 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
TABLE 5 <strong>Global</strong> <strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong> Revenue, by Geography, 2012 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
Browse All Pharmaceutical <strong>Market</strong> Research Reports @<br />
http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html<br />
About Us<br />
Transparency <strong>Market</strong> Research is a market intelligence company providing global business information<br />
reports <strong>and</strong> services. Our exclusive blend of quantitative forecasting <strong>and</strong> trends analysis provides forwardlooking<br />
insight for thous<strong>and</strong>s of decision makers.<br />
We are privileged with highly experienced team of Analysts, Researchers <strong>and</strong> Consultants, who use<br />
proprietary data sources <strong>and</strong> various tools <strong>and</strong> techniques to gather, <strong>and</strong> analyze information. Our<br />
business offerings represent the latest <strong>and</strong> the most reliable information indispensable for businesses to<br />
sustain a competitive edge.<br />
Transparency <strong>Market</strong> Research<br />
13
<strong>Kidney</strong> <strong>Cancer</strong> <strong>Drugs</strong> <strong>Market</strong><br />
Contact<br />
Transparency <strong>Market</strong> Research<br />
90 State Street,<br />
Suite 700,<br />
Albany<br />
NY - 12207<br />
United States<br />
Tel: +1-518-618-1030<br />
USA - Canada Toll Free 866-552-3453<br />
Email: sales@transparencymarketresearch.com<br />
Website: http://www.transparencymarketresearch.com/<br />
Browse The <strong>Market</strong> Research Blog :<br />
http://research<strong>and</strong>reports.wordpress.com/ http://www.transparencymarketresearch.com<br />
Transparency <strong>Market</strong> Research<br />
14
Change language